Navigation Links
Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
Date:11/24/2008

PT. RICHMOND, Calif., Nov. 24 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York City on Tuesday, December 2, 2008 at 8:00 AM Eastern Time.

An audio webcast of the presentation will be available at http://www.piperjaffray.com/conferences. The replay of the presentation will be available for 30 days.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and, on September 30, 2008, Transcept submitted a New Drug Application to the U.S. Food and Drug Administration.

For further information, please visit the company's website at: http://www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, Transcept product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of Transcept product candidates.

     Contacts:

     Transcept Pharmaceuticals, Inc.        The Ruth Group
     Michael Gill                           Investors / Media
     Director of Communications             Stephanie Carrington / Jason Rando
     (510) 215-3575                         (646) 536-7017 / 7025
     mgill@transcept.com                    scarrington@theruthgroup.com
                                            jrando@theruthgroup.com

'/>"/>
SOURCE Transcept Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
2. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
3. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
4. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
8. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
9. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Warner, New Hampshire (PRWEB) , ... May 26, 2016 , ... ... of which are designed, engineered, and manufactured in Warner, New Hampshire at the MadgeTech ... known to provide reliable monitoring solutions trusted by government agencies, including NASA. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising ... 550 employees of Sun Health Senior Living (SHSL) may not share those ... doctor and prescription copays for the year, while holding the line on increasing their ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of ... today announced the organization has earned its ISO 13485 certification, indicating the company’s ... with all rules and policies associated with ISO quality standard 13485. , ...
(Date:5/26/2016)... ... , ... North Cypress Medical Center hosted its 9th Annual Spring ... the help of community partners, the event organizers raised $45,000 for the Lone ... members and their families through health, wellness, and therapeutic support. , A special ...
(Date:5/26/2016)... FL (PRWEB) , ... May 26, 2016 , ... The ... of events featuring guest speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , ... and Regenerative Medicine, and a member of the Institute for Functional Medicine. , He ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... According to a new ... Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, Mechanical, ... Wound), Accessories (Lifting, Transfer) & by End User ... MarketsandMarkets, the patient handling equipment market is expected ... a CAGR of 10.5% during the forecast period ...
(Date:5/23/2016)... , May 23, 2016 Diplomat Pharmacy, Inc. ... annual Fellowship and Internship programs. The hands-on learning experience ... The full-time, paid Fellowship and ... Michigan . Fellows and interns are provided optional ... Flint at the Riverfront Residence Hall ...
(Date:5/23/2016)... 2016 According to market ... Growth and Demand Forecast to 2022 - Industry ... Application (Drug Discovery and Development, Proteomics, Clinical Testing, ... Science and Biotechnology, Academic and Research Institute, Hospitals ... global mass spectrometry market was valued ...
Breaking Medicine Technology: